Scilex Holding (SCLXW) Net Income towards Common Stockholders (2020 - 2026)

Scilex Holding (SCLXW) recorded quarterly Net Income towards Common Stockholders of -$43.3 million in Q1 2026, down 30.68% quarter-over-quarter from -$33.1 million in Q4 2025, and down 65.91% on a YoY basis from -$126.9 million in Q1 2025.

Scilex Holding (SCLXW) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Scilex Holding's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$43.3 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 65.91% year-over-year to -$43.3 million; the TTM figure through Mar 2026 stood at -$419.7 million (down 403.18% YoY), while the FY2025 annual figure was -$402.5 million, down 392.63% from the prior year.
  • Net Income towards Common Stockholders was -$43.3 million for Q1 2026 at Scilex Holding, down from -$33.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $21.5 million in Q3 2022 to a low of -$257.2 million in Q3 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$42.2 million across 5 years, with a median of -$26.1 million in 2025.
  • Biggest YoY gain for Net Income towards Common Stockholders was 7736.6% in 2022; the steepest drop was 10688.09% in 2022.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$17.9 million in 2022, then declined by 19.66% to -$21.4 million in 2023, then grew by 28.25% to -$15.4 million in 2024, then sank by 115.64% to -$33.1 million in 2025, then plunged by 30.68% to -$43.3 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$43.3 million (Q1 2026), -$33.1 million (Q4 2025), and -$257.2 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 2.34 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 5.24 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 697.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -4.21 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 2.02 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -13.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.68 Bn
10 Scilex Holding - - 4.15 Mn -43.27 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -43.27 Mn
Dec 31, 2025 -33.11 Mn
Sep 30, 2025 -257.23 Mn
Jun 30, 2025 -86.06 Mn
Mar 31, 2025 -26.08 Mn
Dec 31, 2024 -15.36 Mn
Sep 30, 2024 -4.39 Mn
Jun 30, 2024 -37.58 Mn
Mar 31, 2024 -24.38 Mn
Dec 31, 2023 -21.40 Mn
Sep 30, 2023 -88.17 Mn
Jun 30, 2023 -26.65 Mn
Mar 31, 2023 -30.75 Mn
Dec 31, 2022 -17.88 Mn
Sep 30, 2022 21.50 Mn
Jun 30, 2022 -17.84 Mn
Mar 31, 2022 -9.14 Mn
Dec 31, 2021 -35.26 Mn
Sep 30, 2021 -281,552.00
Jun 30, 2021 -165,349.00